Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts. Show More...
-
Website https://www.aldeyra.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 2.15 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -7.92 -0.69 -3.14 -3.09 -1.4 -1.65 -1.4 -1.79 -2.24 -2.0 Dividends USD Payout Ratio % * Shares Mil 5.0 5.0 5.0 4.0 9.0 11.0 16.0 22.0 27.0 28.0 Book Value Per Share * USD 1.48 2.95 2.04 2.4 1.09 1.78 1.46 Free Cash Flow Per Share * USD -0.6 -1.06 -1.34 -1.27 -1.36 -1.56 Return on Assets % 38.81 -152.81 -65.37 -70.05 -64.42 -55.85 -71.31 -72.87 Financial Leverage (Average) 2.32 1.4 1.13 1.16 1.12 1.1 1.57 1.45 Return on Equity % -242.41 -77.6 -80.38 -72.95 -61.63 -90.31 -90.32 Return on Invested Capital % -179.0 -71.14 -76.1 -70.38 -62.91 -75.2 -80.6 Interest Coverage -7.5 -66.47 82.97 -20.24 -106.65 -176.23 -195.91 -263.95 -101.9 -51.87 Current Ratio 0.1 5.44 5.41 6.6 13.28 10.93 13.11 11.18 5.82 12.84 Quick Ratio 0.1 5.43 5.39 6.42 13.04 10.84 12.81 11.05 5.68 12.56 Debt/Equity 0.7 0.19 0.05 0.06 0.03 0.3 0.34